Amarin (NASDAQ:AMRN) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Amarin (NASDAQ:AMRN) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.02, Yahoo Finance reports. Amarin had a negative return on equity of 9.48% and a negative net margin of 18.96%. The firm had revenue of $56.52 million during the quarter, compared to analyst estimates of $51.34 million. During the same period last year, the company earned ($0.04) earnings per share.

Amarin Trading Down 0.9 %

NASDAQ AMRN opened at $0.91 on Friday. Amarin has a 12 month low of $0.65 and a 12 month high of $1.49. The stock has a 50-day simple moving average of $0.94 and a 200 day simple moving average of $0.94.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Amarin in a research report on Friday, January 12th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, Amarin presently has a consensus rating of “Hold” and a consensus target price of $1.08.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.